Engineered for full-scale commercial biomanufacturing, this industrial-grade bioreactor serves as the core upstream production equipment for large-volume manufacturing of monoclonal antibodies, recombinant proteins, viral vectors, vaccines, ADC drugs and other biologic therapeutics.
The wetted components adopt hygienic 316L stainless steel with seamless orbital welding and internal electropolishing, fully compliant with cGMP, E&L testing requirements and international biopharmaceutical engineering standards. Equipped with high-efficiency agitation systems, optimized aeration spargers and precise DO/pH/temperature/pressure closed-loop control modules, the unit delivers consistent mass transfer and homogeneous culture environments, maintaining stable cell viability, high product titer and batch-to-batch reproducibility during long-term fed-batch and perfusion continuous production.
Built in strict accordance with ISA-88 batch automation specifications, the integrated PLC control platform supports automated recipe management, batch execution logic, interlock safety protection and unattended continuous operation. All process data is automatically archived with complete audit trails, satisfying regulatory data integrity requirements for FDA, EMA and NMPA filings. The system integrates seamlessly with medium preparation skids, harvest downstream equipment, MES and plant-level central control systems to form a fully closed end-to-end bioprocess line.
Available in customizable large volumetric configurations, the bioreactor supports reliable long-cycle commercial production runs, simplifies on-site qualification and validation workflows, reduces production operating costs, and provides stable, scalable core equipment support for pharmaceutical enterprises’ large-scale commercial launch of biological products.
